Viridian – Talk Bio

Actionable Insights Powered by AI

Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market

1 month ago talkbio0Tagged Antibodies, Biopharma, Clinical Trials, Dosage Forms, Japan, Kissei, Partnership, Thyroid associated opthalmopathies, Veligrotug, Viridian, VRDN-003

Viridian Therapeutics; Kissei Pharmaceutical; veligrotug; VRDN-003; thyroid eye disease; Japan partnership; anti-IGF-1R antibodies; clinical trials; biopharma deal

Viridian’s Veligrotug Demonstrates Efficacy in Second Pivotal Study for Thyroid Eye Disease

9 months ago talkbio0Tagged Antibodies, Clinical Trials, IGF1R protein, human, Phase 3, THRIVE-2, Thyroid associated opthalmopathies, Veligrotug, Viridian

Thyroid Eye Disease, Veligrotug, Viridian Therapeutics, Phase 3 Clinical Trial, THRIVE-2, IGF-1R Antibody